Skip to main content
. 2020 Apr 13;75:e1515. doi: 10.6061/clinics/2020/e1515

Table 4.

Comparison of the intravenous cyclophosphamide and intrathecal methotrexate plus dexamethasone.

Treatment Number of patients Response duration (days) Effective rate (%) Incidence of adverse events (%)
CYC 72 5.2±1.03 72.2 17.3
MTX+DXM 84 2.3±0.95 90.5 6.0
χ2 or t - 6.539 4.386 5.112
p - <0.001 0.036 0.024